As of 2025-03-15, the EV/EBITDA ratio of Kala Pharmaceuticals Inc (KALA) is -0.61. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. KALA's latest enterprise value is 25.83 mil USD. KALA's TTM EBITDA according to its financial statements is -42.64 mil USD. Dividing these 2 quantities gives us the above KALA EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | - | - |
| Forward P/E multiples | - | - |
| Fair Price | - | - |
| Upside | - | - |
| Date | EV/EBITDA |
| 2025-03-04 | -0.67 |
| 2025-03-03 | -0.67 |
| 2025-02-28 | -0.66 |
| 2025-02-27 | -0.67 |
| 2025-02-26 | -0.63 |
| 2025-02-25 | -0.61 |
| 2025-02-24 | -0.62 |
| 2025-02-21 | -0.62 |
| 2025-02-20 | -0.65 |
| 2025-02-19 | -0.64 |
| 2025-02-18 | -0.70 |
| 2025-02-14 | -0.87 |
| 2025-02-13 | -0.78 |
| 2025-02-12 | -0.73 |
| 2025-02-11 | -1.22 |
| 2025-02-10 | -1.14 |
| 2025-02-07 | -1.24 |
| 2025-02-06 | -1.20 |
| 2025-02-05 | -1.06 |
| 2025-02-04 | -1.00 |
| 2025-02-03 | -0.99 |
| 2025-01-31 | -0.98 |
| 2025-01-30 | -1.02 |
| 2025-01-29 | -0.93 |
| 2025-01-28 | -0.92 |
| 2025-01-27 | -0.86 |
| 2025-01-24 | -0.83 |
| 2025-01-23 | -0.83 |
| 2025-01-22 | -0.77 |
| 2025-01-21 | -0.77 |
| 2025-01-17 | -0.71 |
| 2025-01-16 | -0.67 |
| 2025-01-15 | -0.69 |
| 2025-01-14 | -0.62 |
| 2025-01-13 | -0.61 |
| 2025-01-10 | -0.64 |
| 2025-01-08 | -0.64 |
| 2025-01-07 | -0.77 |
| 2025-01-06 | -0.75 |
| 2025-01-03 | -0.80 |
| 2025-01-02 | -0.77 |
| 2024-12-31 | -0.66 |
| 2024-12-30 | -0.65 |
| 2024-12-27 | -0.67 |
| 2024-12-26 | -0.66 |
| 2024-12-24 | -0.56 |
| 2024-12-23 | -0.53 |
| 2024-12-20 | -0.52 |
| 2024-12-19 | -0.53 |
| 2024-12-18 | -0.49 |